A phase 1 and 2 trial of rubidazone in patients with acute leukemia.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000187:drug effects; D003630:Daunorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004317:Doxorubicin / Q000494:pharmacology; D004341:Drug Evaluation; D005260:Female; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008099:Liver / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009092:Mucous Membrane / Q000187:drug effects; D012075:Remission, Spontaneous; D013997:Time Factors
D004317:Doxorubicin; C002205:zorubicin; D003630:Daunorubicin